A detailed history of Psi Advisors, LLC transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Psi Advisors, LLC holds 200 shares of TGTX stock, worth $3,910. This represents 0.0% of its overall portfolio holdings.

Number of Shares
200
Previous 1,200 83.33%
Holding current value
$3,910
Previous $20,000 85.0%
% of portfolio
0.0%
Previous 0.01%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 24, 2024

SELL
$13.02 - $21.3 $13,020 - $21,300
-1,000 Reduced 83.33%
200 $3,000
Q4 2023

Feb 01, 2024

SELL
$6.68 - $18.81 $501 - $1,410
-75 Reduced 5.88%
1,200 $20,000
Q2 2022

Jul 18, 2022

BUY
$3.74 - $10.66 $3,740 - $10,660
1,000 Added 363.64%
1,275 $5,000
Q1 2022

Apr 20, 2022

SELL
$7.81 - $20.45 $7,810 - $20,450
-1,000 Reduced 78.43%
275 $3,000
Q4 2021

Feb 11, 2022

SELL
$15.2 - $35.51 $12,540 - $29,295
-825 Reduced 39.29%
1,275 $24,000
Q3 2021

Nov 12, 2021

BUY
$21.78 - $40.45 $45,738 - $84,945
2,100 New
2,100 $70,000

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $2.84B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Psi Advisors, LLC Portfolio

Follow Psi Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Psi Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Psi Advisors, LLC with notifications on news.